Haemostatix is a startup, most recent round Acquired, 1 tracked investor.
Haemostatix is a startup. Haemostatix has been acquired. Brouky records 1 investor associated with the company.
Haemostatix developed first-in-class clotting agents for the treatment of bleeding (haemostasis). The company was an early-stage biotechnology developer and was sold to Ergomed plc in May 2016.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.